分组1 - Codexis reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.01 per share, compared to a loss of $0.13 per share a year ago, representing an earnings surprise of +2,100.00% [1] - The company posted revenues of $38.92 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.61%, and showing a significant increase from year-ago revenues of $21.46 million [2] - Codexis shares have declined approximately 23.9% since the beginning of the year, while the S&P 500 has only declined by 0.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $19.02 million, and for the current fiscal year, it is -$0.33 on revenues of $70.17 million [7] - The Medical - Biomedical and Genetics industry, to which Codexis belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

分组1 - Liquidia Corporation reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, compared to a loss of $0.46 per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $92.02 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 19.34%, compared to year-ago revenues of $2.92 million [2] - Liquidia Corporation has surpassed consensus EPS estimates two times and revenue estimates three times over the last four quarters [2] 分组2 - The current consensus EPS estimate for the coming quarter is $0.20 on revenues of $79.43 million, and for the current fiscal year, it is $1.05 on revenues of $368.29 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 46% of over 250 Zacks industries, indicating that the industry outlook can materially impact stock performance [8]

分组1 - Beam Therapeutics Inc. reported a quarterly loss of $0.1 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.13, representing an earnings surprise of +91.15% [1] - The company posted revenues of $114.11 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 676.25%, compared to revenues of $30.07 million a year ago [2] - Beam Therapeutics shares have increased by approximately 2.2% since the beginning of the year, while the S&P 500 has declined by 0.1% [3] 分组2 - The earnings outlook for Beam Therapeutics is uncertain, with current consensus EPS estimates at -$1.14 on revenues of $15.49 million for the coming quarter and -$4.63 on revenues of $55.85 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The estimate revisions trend for Beam Therapeutics was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]

分组1 - Codexis reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, and compared to a loss of $0.16 per share a year ago, indicating a significant earnings surprise of -25% [1] - The company generated revenues of $7.54 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 28.99%, and a decline from year-ago revenues of $17.07 million [2] - Codexis shares have decreased by approximately 46.3% since the beginning of the year, contrasting with the S&P 500's gain of 0.1% [3] 分组2 - The earnings outlook for Codexis is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Codexis is currently favorable, resulting in a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] - The current consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $14.68 million, and for the current fiscal year, it is -$0.62 on revenues of $65.74 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Codexis belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a positive outlook for stocks within this sector [8] - Roivant Sciences Ltd., another company in the same industry, is expected to report a quarterly loss of $0.16 per share, reflecting a year-over-year change of +30.4%, with revenues projected to be $67.33 million, up 132.7% from the previous year [9]